Massachusetts 2025-2026 Regular Session

Massachusetts House Bill H779 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	1 of 1
2	2	HOUSE DOCKET, NO. 2870 FILED ON: 1/16/2025
3	3	HOUSE . . . . . . . . . . . . . . . No. 779
4	4	The Commonwealth of Massachusetts
5	5	_________________
6	6	PRESENTED BY:
7	7	Kate Lipper-Garabedian
8	8	_________________
9	9	To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
10	10	Court assembled:
11	11	The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
12	12	An Act to protect 340B providers in the MassHealth program.
13	13	_______________
14	14	PETITION OF:
15	15	NAME:DISTRICT/ADDRESS :DATE ADDED:Kate Lipper-Garabedian32nd Middlesex1/16/2025 1 of 2
16	16	HOUSE DOCKET, NO. 2870 FILED ON: 1/16/2025
17	17	HOUSE . . . . . . . . . . . . . . . No. 779
18	18	By Representative Lipper-Garabedian of Melrose, a petition (accompanied by bill, House, No.
19	19	779) of Kate Lipper-Garabedian relative to hospital access to discounted purchase of prescription
20	20	drugs. Elder Affairs.
21	21	The Commonwealth of Massachusetts
22	22	_______________
23	23	In the One Hundred and Ninety-Fourth General Court
24	24	(2025-2026)
25	25	_______________
26	26	An Act to protect 340B providers in the MassHealth program.
27	27	Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
28	28	of the same, as follows:
29	29	1 Section 13L of chapter 118E of the General Laws is hereby amended by striking the
30	30	2section in its entirety and replacing with the following:
31	31	3 “The secretary of health and human services, hereinafter “the secretary”, shall not restrict
32	32	4or limit an eligible hospital’s access to the discounted purchase of prescription drugs to the full
33	33	5extent permitted under section 340B of the Public Health Service Act, as codified under 42
34	34	6U.S.C. 256b unless the secretary provides the following not less than 180 days before the
35	35	7proposed effective date of the limitation or restriction: (i) notice to eligible hospitals of the
36	36	8proposed restriction or limitation; and (ii) a report with the joint committee on health care
37	37	9financing and the senate and house committees on ways and means detailing: (A) the proposed
38	38	10restriction or limitation; (B) the anticipated aggregate savings to the commonwealth; (C) the
39	39	11estimated fiscal impact of the restriction or limitation on each affected hospital; and (D) the
40	40	12manner in which the secretary plans to mitigate the fiscal impact, which may include measures to 2 of 2
41	41	13maintain savings already achieved by providers under said 42 U.S.C. 256b. In addition to the
42	42	14foregoing, the secretary shall not take any actions, including through managed care entities as
43	43	15defined in section 13D ½ of this chapter, that restrict or limit reimbursement or coverage of a
44	44	16drug purchased under 42 U.S.C. 256b when furnished to MassHealth members, unless the
45	45	17specific drug subject to restriction or limitation (i) costs $100,000 or more per utilizer per year
46	46	18and is one of up to 25 drugs designated by the executive office for exclusion from MassHealth
47	47	19members, or (ii) is one of the seven GLP-1 Agonist drugs designated by the executive office that
48	48	20is restricted from reimbursement if purchased under 42 U.S.C. 256b effective July 1, 2024.”